文献速递其他结缔组织病自身炎症与 IgG4 相关病

肌炎特异性自身抗体对青少年特发性炎症性肌病长期预后的临床影响:多中心研究

Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

日本九家儿童风湿病中心回顾性纳入96例JIIM患者,其中85例检出MSA;抗MDA5、抗TIF1γ和抗NXP2占90%以上。抗MDA5抗体患者更易合并ILD、接受多药治疗(含静脉CYC),但更易达到无药缓解且复发率较低。

要点

  • 抗MDA5是日本JIIM最常见MSA类型,常合并ILD并需多药治疗。
  • 抗MDA5患者无药缓解率更高(29% vs 21%)、复发率更低(26% vs 44%)。
  • 抗TIF1γ和抗NXP2患者多接受糖皮质激素联合MTX治疗。

核心结论

  • 抗MDA5抗体是日本JIIM最常见MSA类型,以起病时ILD、多药治疗(含静脉CYC)、无药缓解和较低复发频率为特征。
  • 其他MSA类型需要新的治疗策略。

研究设计与样本

  • 多中心回顾性研究,纳入日本九家儿童风湿病中心的JIIM患者。
  • 纳入经免疫沉淀法测定活动期储存血清MSA谱的患者,96例符合分析条件,85例检出MSA。

主要发现

  • 抗MDA5(n=31)、抗TIF1α和/或γ亚单位(TIF1γ)(n=25)及抗NXP2(n=25)抗体占90%以上。
  • 各MSA组初期最常见体征为Gottron丘疹和甲周毛细血管异常。
  • ILD是抗MDA5抗体患者的最高风险因素。
  • 抗MDA5患者较其他人更易达到无药缓解(29% vs 21%),复发较少(26% vs 44%)。

关键数值与推荐

  • 抗TIF1γ或抗NXP2抗体患者接受糖皮质激素和MTX治疗。
  • 半数抗MDA5抗体患者接受超过三种药物(包括静脉CYC),尤其是合并ILD者。

临床怎么用

  • 对JIIM患者应检测MSA谱以指导预后判断和治疗分层。
  • 抗MDA5抗体患者需警惕ILD并可能需多药联合治疗,但长期预后可能较好。
  • 抗TIF1γ和抗NXP2患者常用糖皮质激素联合MTX。

局限性

  • 回顾性研究设计。
  • 样本量有限(96例符合分析,85例检出MSA)。
  • 仅纳入日本九家中心患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to investigate the clinical characteristics, treatment and prognosis of juvenile idiopathic inflammatory myopathies (JIIM) in Japan for each myositis-specific autoantibody (MSA) profile. METHODS: A multicentre, retrospective study was conducted using data of patients with JIIM at nine paediatric rheumatology centres in Japan. Patients with MSA profiles, determined by immunoprecipitation using stored serum from the active stage, were included. RESULTS: MSA were detected in 85 of 96 cases eligible for the analyses. Over 90% of the patients in this study had one of the following three MSA types: anti-melanoma differentiation-associated protein 5 (MDA5) (n = 31), anti-transcriptional intermediary factor 1 alpha and/or gamma subunits (TIF1γ) (n = 25) and anti-nuclear matrix protein 2 (NXP2) (n = 25) antibodies. Gottron papules and periungual capillary abnormalities were the most common signs of every MSA group in the initial phase. The presence of interstitial lung disease (ILD) was the highest risk factor for patients with anti-MDA5 antibodies. Most patients were administered multiple drug therapies: glucocorticoids and MTX were administered to patients with anti-TIF1γ or anti-NXP2 antibodies. Half of the patients with anti-MDA5 antibodies received more than three medications including i.v. CYC, especially patients with ILD. Patients with anti-MDA5 antibodies were more likely to achieve drug-free remission (29 vs 21%) and less likely to relapse (26 vs 44%) than others. CONCLUSION: Anti-MDA5 antibodies are the most common MSA type in Japan, and patients with this antibody are characterized by ILD at onset, multiple medications including i.v. CYC, drug-free remission, and a lower frequency of relapse. New therapeutic strategies are required for other MSA types.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yamasaki Y, Kobayashi N, Akioka S, et al. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology (Oxford). 2021. PMID: 33576399. doi:10.1093/rheumatology/keab108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。